🇺🇸 FDA
Patent

US 9820951

Pulmonary disease treatment and diagnosis based on Arhgef1

granted A61KA61K31/18A61K31/192

Quick answer

US patent 9820951 (Pulmonary disease treatment and diagnosis based on Arhgef1) held by The Regents of the University of Colorado, a Body Corporate expires Mon Nov 16 2037 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of Colorado, a Body Corporate
Grant date
Tue Nov 21 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 16 2037 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
5
CPC classes
A61K, A61K31/18, A61K31/192, A61K31/403, A61K31/4178